Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Open Access
- 1 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (5), 717-722
- https://doi.org/10.1086/655470
Abstract
In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected polymorphisms and treatment responses were characterized by competing risk methodology. Association analyses involved 821 individuals (317 for pharmacokinetics and 643 for treatment response). Models that included CYP2B6 516/983 genotype best predicted pharmacokinetics. Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants.Keywords
This publication has 14 references indexed in Scilit:
- Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African AmericansThe Journal of Infectious Diseases, 2009
- Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected IndividualsCancer Cell, 2007
- MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide PolymorphismsClinical Chemistry, 2007
- Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 InfectionA Randomized Controlled TrialJAMA, 2006
- Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2005
- Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected IndividualsAnnals of Internal Medicine, 2005
- Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.2004
- Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionNew England Journal of Medicine, 2003
- Methods for Integration of Pharmacokinetic and Phenotypic Information in the Treatment of Infection with Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyThe Lancet, 2002